Slide 1: Investor Presentation May 2021
© 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o INVESTOR P R ESE N T A TIO N MAY 2021 WHERE TELEHEALTH STOPS, WE GO
Slide 2: Disclaimer
Disclaimer © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 1 This presentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba “DocGo”), Motion Acquisition Corp. (“Motion”), and a wholly owned subsidiary of Motion, dated as of March 9, 2021.
Slide 3: Disclaimer (cont'd)
Disclaimer (cont’d) © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 2 Market and Industry Data Market data and industry data used throughout this presentation is based on information derived from third party sources, the knowledge of the management teams of DocGo and Motion regarding their r
Slide 4: Disclaimer (cont'd)
Disclaimer (cont’d) © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 3 Forward Looking Statements (cont’d) Any financial projections in this presentation are forward - looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies,
Slide 5: Our Brand and Company Culture
Our Brand and Company Culture Where basic telehealth providers stop, we go. Where public health emergencies need a response, we go. Where homebound populations benefit from onsite treatment, we go. Where long waits in busy emergency rooms do more harm than good, we go. And when all reason says it ca
Slide 6: DocGo at a Glance
DocGo at a Glance Key Highlights (a) As of May 15, 2021. Leveraging a proprietary technology platform and care logistics expertise to provide high quality, efficient “last - mile” healthcare delivery services 2,200,000+ Cumulative Patient Interactions (a) 82%+ 2019 - 2021E Revenue CAGR 2,000+ Employ
Slide 7: Where Traditional Care Stops, DocGo Keeps Going
Where Traditional Care Stops, DocGo Keeps Going Limited options to get treated at home or on - site Current telehealth offerings do not provide immediate in - person care or follow - up as needed DocGo TeleHealth Plus Solution x Mobility solutions that are enabled by highly coordinated and effic
Slide 8: For Patients… For Providers…
For Patients… ✓ At home treatment is convenient, comfortable and results in an improved patient experience ✓ Accessibility to health professionals promotes better patient compliance with discharge treatment plans ✓ More focused care reduces unnecessary hospital readmissions For Providers… ✓ DocGo em
Slide 9: Differentiated Approach Creates Efficiency and Cost Savings
Differentiated Approach Creates Efficiency and Cost Savings Vaccination Bloodwork Oral Medicine Administration EKG IV Hydration DocGo Wound Care Industry Average Enabling Dramatic TeleHealth Plus Cost Advantage Cost per patient EMTs, Paramedics, CNAs and LPNs have significantly lower hourly costs Nu
Slide 10: Transportation Serves as Foundation for Operational Leverage
Transportation Serves as Foundation for Operational Leverage Fully integrated solution provider facilitating high - quality, efficient patient transportation across all sites of care Pediatrics / Neonatal Intensive Care Unit Critical Care Transport Car Wheelchair Accessible Vehicle Ambulette Basic L
Slide 11: Purpose-Built Technology Platform
Purpose - Built Technology Platform For Patients and Families Core Functionality and Benefits x Streamlined ordering process to reduce burden on © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 10 sta f f x Integration of electronic health records to enhance functionality & billing/collection
Slide 12: Our Footprint and Reach
Our Footprint and Reach Our Footprint Currently operating in 23 US states and the UK Licensed to operate in 29 states; licenses pending in 14 additional states <1% market penetration today Mobility Only TeleHealth Plus Only Mobility and TeleHealth Plus © 2 0 2 1 A l l R i g h t s R e s e r v e d – D
Slide 13: JV Partners Help Drive Predictable Growth
JV Partners Help Drive Predictable Growth Highly recurring and predictable revenue National footprint across JVs Evergreen contract structure with multi - year cancellation notice periods $500M+ per year combined reve n ue opp ort unity (b) DocGo is in advanced talks with several large hospital syst
Slide 14: Illustrative Customers & Partners
Illustrative Customers & Partners © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 13 Tailored Go - to - Market for each Customer Segment Health Systems Enterprise / Corporates Government
Slide 15: Significant Market Opportunity
Significant Market Opportunity U.S. Total Addressable Market Source: McKinsey “Telehealth: A quarter - trillion - dollar - post - COVID - 19 reality” report published 5/1/20 and management estimates. $95 billion market opportunity leaving long runway for rapid growth Last - Mile Urgent Care $35 B La
Slide 16: Experienced Management Team
Experienced Management Team Stan Vashovsky Co - Founder, Chief Executive Officer Andre Oberholzer Chief Financial Officer • Founded DocGo in 2015 with the vision to revolutionize medical transportation and healthcare delivery • Previously an executive for services innovations at Philips Healthcare •
Slide 17: Key Takeaways
Key Takeaways Significant market and growth opportunity with limited current market penetration Early stages of accelerating recurring revenue growth Unique value proposition to healthcare systems and patients Defensible competitive advantages in technology / network Mission - driven company with ex
Slide 18: Financial Overview
SD, Financial Overview
Slide 19: Highly Attractive Financial Characteristics
Highly Attractive Financial Characteristics Significant revenue growth opportunity with limited existing penetration Visibility to recurring revenue growth with existing JV partners Scalable business model with robust operating leverage Capital efficient approach enables rapid expansion in existing
Slide 20: Recurring, Predictable Revenue Model
Recurring, Predictable Revenue Model • Data - driven market - by - market approach to identify highly visible, recurring transportation needs by provider • Base rate and average transport distance largely dependent upon geography • Base rate typically references a Medicare fee schedule and has histo
Slide 21: Strong Growth Trajectory and Margin Profile
($9) $4 $38 2 0 20A 2 0 21E 2 0 22E $8 $13 $32 $64 $117 2 0 19A 2 0 20A 2 0 21E 2 0 22E ($17) ($7) $6 $43 2 0 19A 2 0 20A 2 0 21E 2 0 22E Strong Growth Trajectory and Margin Profile Revenue Gross Profit 28.5% 21.4% 95.3% 70.2% 71.7% 20.8% 27.3% 33.9% 40.0% 44.0% 2 0 18A % margin 2 0 18A % growth • S
Slide 22: Preliminary First Quarter 2021 Financial Highlights and Full-Year Outlook
$13.4 $49.6 Q1 2020 Q1 2021 ($4.5) Q1 2020 $0.7 Q1 2021 Preliminary First Quarter 2021 Financial Highlights and Full - Year Outlook • Excluding Covid - related testing, Q1 revenue more than doubled • TeleHealth Plus revenue increased to nearly $30 million, compared to $0.5 million in Q1 2020 • DocGo
Slide 23: Transaction Overview
>, Transaction Overview
Slide 24: Estimated Transaction Sources & Uses
Estimated Transaction Sources & Uses ($ in millions) Sources Post - Money Valuation at Close ($ in millions) Pro forma Transaction (b) Illustrative Post - Transaction Ownership Uses SPAC Cash in Trust $115 PIPE Investor Cash $125 Total Sources $240 Cash to Balance Sheet $205 Transaction Expenses $35
Slide 25: Comparable Company Benchmarking
DocGo Healthcare Peers 30% 37% Virtual Care Peers 48% 45% Peer Gro u p Average 37% 2019A - 2022E Revenue CAGR 77% 55% 21% 31% DocGo Oak Street (a)(b) One Medical Accolade Signify (c) Teladoc Hims&Hers Amwell Peer Gr o up Median 2021E Gross Profit Margin 40% 7% 39% 45% 49% 68% 71% 37% 45% DocGo Oak S
Slide 26: Comparable Company Benchmarking: Multiples
Note: Excludes multiples >100.0x. (a) Excludes the pending acquisition of Plushcare. Source: Company information, FactSet. Market data as of 18 - May - 21. EV/2021E Revenue DocGo 5.6x 11.9x Healthcare Peers 9.8x 10.9x 8.2x Virtual Care Peers 12.2x 8.0x 8.9x Peer Gro u p Median 9.8x DocGo Oak Street
Slide 27: Appendices
>, Appendices
Slide 28: Non-GAAP Adjusted EBITDA Reconciliation
© 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o ($ in thousands) CY2020E Net Loss Attributable to DocGo ($15,049) (+) Loss of JV (213) Net Loss (GAAP) ($15,262) (+) Net Interest Expense / (Income) 608 (+) Income Tax 167 (+) Depreciation & Amortization 5,689 EBITDA ($8,798) (+) Non - Cash Sto